Jupiter Asset Management Ltd. Sells 128,669 Shares of CareDx, Inc. $CDNA

Jupiter Asset Management Ltd. decreased its stake in CareDx, Inc. (NASDAQ:CDNA) by 64.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 69,715 shares of the company’s stock after selling 128,669 shares during the period. Jupiter Asset Management Ltd. owned approximately 0.14% of CareDx worth $1,014,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Goldman Sachs Group Inc. grew its position in CareDx by 18.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,110,014 shares of the company’s stock worth $19,703,000 after purchasing an additional 170,504 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of CareDx by 11.3% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 133,966 shares of the company’s stock valued at $2,378,000 after buying an additional 13,619 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in shares of CareDx in the second quarter valued at about $352,000. AlphaQuest LLC grew its position in CareDx by 40.0% during the second quarter. AlphaQuest LLC now owns 9,576 shares of the company’s stock worth $187,000 after buying an additional 2,736 shares in the last quarter. Finally, Envestnet Asset Management Inc. increased its stake in CareDx by 17.7% during the second quarter. Envestnet Asset Management Inc. now owns 22,489 shares of the company’s stock valued at $439,000 after acquiring an additional 3,389 shares during the period.

CareDx Price Performance

CareDx stock opened at $18.80 on Monday. The firm has a market capitalization of $966.88 million, a P/E ratio of 15.80 and a beta of 2.51. The stock has a fifty day moving average price of $19.71 and a two-hundred day moving average price of $16.64. CareDx, Inc. has a 52-week low of $10.96 and a 52-week high of $24.02.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on CDNA. Wells Fargo & Company lifted their price objective on CareDx from $14.00 to $18.00 and gave the stock an “equal weight” rating in a report on Monday, December 15th. BTIG Research raised their target price on CareDx from $22.00 to $25.00 and gave the stock a “buy” rating in a research report on Thursday, November 6th. Weiss Ratings reissued a “hold (c-)” rating on shares of CareDx in a report on Monday, December 29th. Craig Hallum cut shares of CareDx from a “buy” rating to a “hold” rating and set a $26.00 price objective for the company. in a research note on Tuesday, January 6th. Finally, Wall Street Zen lowered shares of CareDx from a “buy” rating to a “hold” rating in a research report on Saturday, February 7th. Three research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $26.67.

Insider Buying and Selling at CareDx

In other news, CEO John Walter Hanna, Jr. sold 19,280 shares of CareDx stock in a transaction that occurred on Thursday, January 22nd. The shares were sold at an average price of $21.16, for a total value of $407,964.80. Following the completion of the transaction, the chief executive officer owned 597,405 shares in the company, valued at approximately $12,641,089.80. The trade was a 3.13% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders have sold a total of 29,636 shares of company stock worth $625,949 over the last three months. Company insiders own 4.40% of the company’s stock.

About CareDx

CareDx, Inc (NASDAQ: CDNA) is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non‐invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post‐transplant journey.

The company’s core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor‐derived cell‐free DNA assay used primarily in kidney transplant monitoring.